SESSION TITLE: Monday Electronic Posters 1 SESSION TYPE: Original Inv Poster Discussion PRESENTED ON: 10/21/2019 02:30 PM - 03:15 PM PURPOSE: Management of primary spontaneous pneumothorax (PSP) differs widely among medical centers and between specialties and disagreement regarding optimal initial management of PSP continues to exist. To improve management of PSP patients, this study assessed which initial management method leads to less recurrences and evaluated the significance of each recurrence. METHODS: Medical records at a tertiary-care, community hospital, were analyzed for all patients with PSP from years 2009-2015. Recurrence rate with type of intervention necessitated for each recurrence and demographic/clinical characteristics were assessed. Management types were medical observation (MO), chest tube placement (CTP), or surgical intervention (SI). Fisher’s exact test was utilized to compare group characteristics. A multivariate logistic regression model was fitted for the primary outcome of recurrence. RESULTS: 213 patients treated for PSP were identified with an average follow-up period of 6.6 years. Of these patients, 15.3%, 43.3%, and 41.3% underwent MO, CTP, and SI, respectively. PSP that were treated medically were smaller in size, but blebs were more prevalent in the SI group. Recurrence rate was significantly lower in the SI group, 11.7%, compared to the MO and CTP groups, 43.5%, 44.4%, respectively (p<0.001). Of those recurrences that initially underwent MO or CTP, 70% and 96.4%, respectively, required a CTP or SI at time of recurrence. The most common management at time or recurrence was SI. CONCLUSIONS: Disagreement and paucity in the literature exists regarding the best initial management of PSP. This is the largest study with the longest follow-up period that addresses this issue. Results from this study demonstrate a nearly 4x higher rate of recurrence with MO and CTP management compared to SI. Additionally, the majority of recurrences managed with MO or CTP initially required invasive management. These findings support early surgical consultation and SI for PSP. CLINICAL IMPLICATIONS: There is great variability in PSP management between individual practitioners and between institutions. Some have elected for non-operative management of most PSPs, while others elect for surgical management at initial presentation. There is a current dearth of studies addressing this issue. This study is the largest patient population with the longest follow-up period of its kind. Results demonstrate a nearly four times lower recurrence rate when a patient was managed surgically. Some have suggested that higher recurrence rates in the MO and CTP groups are not significant, as these recurrences often do not require SI. This study found in fact the majority of recurrences underwent SI and 70-96.4% of recurrences required invasive management. These findings support early surgical consultation and SI. These findings can provide clinicians with data that can be utilized in the creation of treatment algorithms for the management of PSP. DISCLOSURES: No relevant relationships by Devon Collins, source=Web Response No relevant relationships by Sameer Javed, source=Web Response Consultant relationship with Medtronic Please note: $20001 - $100000 Added 03/14/2019 by Sandeep Khandhar, source=Web Response, value=Consulting fee Consultant relationship with Auris Robotics Please note: $5001 - $20000 Added 03/14/2019 by Sandeep Khandhar, source=Web Response, value=Consulting fee Advisory Committee Member relationship with Boston Scientific Please note: $1001 - $5000 Added 03/14/2019 by Sandeep Khandhar, source=Web Response, value=Consulting fee Speaker/Speaker's Bureau relationship with Bard Please note: $1001 - $5000 Added 03/14/2019 by Sandeep Khandhar, source=Web Response, value=Consulting fee Stock Holder relationship with Transenterix Please note: $5001 - $20000 Added 03/14/2019 by Sandeep Khandhar, source=Web Response, value=Stock Consultant relationship with Medtronic Please note: $1001 - $5000 Added 03/14/2019 by Sandeep Khandhar, source=Web Response, value=Travel Board Member relationship with bh Please note: $1-$1000 Added 03/14/2019 by Sandeep Khandhar, source=Web Response, value=Consulting fee Removed 03/14/2019 by Sandeep Khandhar, source=Web Response No relevant relationships by Chang Liu, source=Admin input Consultant relationship with Medtronic Corporation Please note: $20001 - $100000 Added 10/20/2018 by Amit Mahajan, source=Web Response, value=Consulting fee Consultant relationship with Auris Robotics Please note: $5001 - $20000 Added 10/20/2018 by Amit Mahajan, source=Web Response, value=Consulting fee Consultant relationship with Boston Scientific Please note: $1001 - $5000 Added 10/20/2018 by Amit Mahajan, source=Web Response, value=Consulting fee Advisory Committee Member relationship with Biodesix Please note: $5001 - $20000 Added 10/20/2018 by Amit Mahajan, source=Web Response, value=Consulting fee No relevant relationships by Jay Patel, source=Web Response No relevant relationships by Josh Stodghill, source=Web Response
Read full abstract